AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.
You may also be interested in...
The failure of veliparib in Phase III studies of squamous NSCLC and triple-negative breast cancer is a blow for AbbVie's oncology pipeline, but may not have implications for other PARP inhibitors in new tumor types.
Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
The latest drug development news and highlights from our FDA Performance Tracker.